These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease. Smiley DA; Rodriguez CM; Maurer MS Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137 [TBL] [Abstract][Full Text] [Related]
24. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. Stevenson LW J Heart Lung Transplant; 1991; 10(3):468-76. PubMed ID: 1854776 [TBL] [Abstract][Full Text] [Related]
25. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. Oghina S; Bougouin W; Bézard M; Kharoubi M; Komajda M; Cohen-Solal A; Mebazaa A; Damy T; Bodez D JACC Heart Fail; 2021 Mar; 9(3):169-178. PubMed ID: 33549560 [TBL] [Abstract][Full Text] [Related]
26. [Anesthetic management for pneumonectomy in a patient with cardiac amyloidosis]. Tomita Y; Shimode N; Nomura H; Ueki R; Tatara T; Tashiro C Masui; 2010 Dec; 59(12):1514-7. PubMed ID: 21229694 [TBL] [Abstract][Full Text] [Related]
27. Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Konstam MA; Weiland DS; Conlon TP; Martin TT; Cohen SR; Eichhorn EJ; Isner JM; Zile MR; Salem DN Am J Cardiol; 1987 May; 59(12):1131-7. PubMed ID: 3578055 [TBL] [Abstract][Full Text] [Related]
28. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study. Brent BN; Berger HJ; Matthay RA; Mahler D; Pytlik L; Zaret BL Am J Cardiol; 1983 Jun; 51(10):1682-9. PubMed ID: 6407295 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. Perlini S; Salinaro F; Musca F; Mussinelli R; Boldrini M; Raimondi A; Milani P; Foli A; Cappelli F; Perfetto F; Palladini G; Rapezzi C; Merlini G J Hypertens; 2014 May; 32(5):1121-31; discussion 1131. PubMed ID: 24509117 [TBL] [Abstract][Full Text] [Related]
30. Cardiac amyloidosis-an underdiagnosed cause of heart failure in the elderly. Nazir T; Nuffati M J Saudi Heart Assoc; 2020; 32(1):98-102. PubMed ID: 33154899 [TBL] [Abstract][Full Text] [Related]
31. Cardiac amyloidosis, contrictive pericarditis and restrictive cardiomyopathy. Meaney E; Shabetai R; Bhargava V; Shearer M; Weidner C; Mangiardi LM; Smalling R; Peterson K Am J Cardiol; 1976 Nov; 38(5):547-56. PubMed ID: 983951 [TBL] [Abstract][Full Text] [Related]
32. Drug treatment of patients with decompensated heart failure. Mills RM; Hobbs RE Am J Cardiovasc Drugs; 2001; 1(2):119-25. PubMed ID: 14728041 [TBL] [Abstract][Full Text] [Related]
33. The role of echocardiography and 99mTc-HDP scintigraphy in non-invasive diagnosis of cardiac amyloidosis: A case series and literature review. Costache II; Buburuz AM; Crisu D; Statescu AM; Ungureanu C; Aursulesei V Medicine (Baltimore); 2019 Sep; 98(38):e17256. PubMed ID: 31567998 [TBL] [Abstract][Full Text] [Related]
34. Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report. Imamura T; Izumida T; Hori M; Tanaka S; Kinugawa K J Int Med Res; 2022 Jul; 50(7):3000605221078484. PubMed ID: 35904051 [TBL] [Abstract][Full Text] [Related]
35. Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management. Laptseva N; Rossi VA; Sudano I; Schwotzer R; Ruschitzka F; Flammer AJ; Duru F J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048664 [TBL] [Abstract][Full Text] [Related]
36. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. Johnson W; Omland T; Hall C; Lucas C; Myking OL; Collins C; Pfeffer M; Rouleau JL; Stevenson LW J Am Coll Cardiol; 2002 May; 39(10):1623-9. PubMed ID: 12020489 [TBL] [Abstract][Full Text] [Related]
37. Nitroprusside in decompensated heart failure: what should a clinician really know? Opasich C; Cioffi G; Gualco A Curr Heart Fail Rep; 2009 Sep; 6(3):182-90. PubMed ID: 19723460 [TBL] [Abstract][Full Text] [Related]
38. [Therapy of advanced heart failure adapted to hemodynamic objectives acquired by invasive hemodynamic monitoring]. Almeida Júnior GL; Esporcatte R; Rangel FO; Rocha RM; Gouvêa e Silva Gde M; Tura BR; Jorge JK; Drumond LE; Albanesi Filho FM Arq Bras Cardiol; 2005 Oct; 85(4):247-53. PubMed ID: 16283030 [TBL] [Abstract][Full Text] [Related]
39. Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance. Miller RR; Vismara LA; Zelis R; Amsterdam EA; Mason DT Circulation; 1975 Feb; 51(2):328-36. PubMed ID: 1112013 [TBL] [Abstract][Full Text] [Related]
40. [Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy]. Moriuchi M; Saito S; Tamura Y; Kaseda N; Tsuji M; Tokutake E; Yumikura S; Hibiya K; Ozawa Y; Hatano M J Cardiogr Suppl; 1986; (9):77-85. PubMed ID: 3093596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]